Login

Financial Snapshot

Revenue
TTM
$0.00
Gross Margin
Last 4 Quarters
N/A
Net Income
TTM
-$108.8M
Current Assets
2025 Q4
$121.2M
Current Liabilities
2025 Q4
$18.59M
Current Ratio
2025 Q4
652.2%
Total Assets
2025 Q4
Total Liabilities
2025 Q4
Book Value
2025 Q4
130.9M
Cash
2025 Q4
$86.42M
P/E
Last 4 Quarters
N/A
Free Cash Flow
TTM
-$60.68M

Stock Price

Loading...
Market Cap: $557.55 Million

About Agomab Therapeutics NV

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases. The firm is engaged in research and development services creating therapies for fibrotic and inflammatory diseases. Its activities include discovery research to identify drug candidates that act on pathways involved in fibrosis and tissue repair, such as organ restricted small molecules and growth factor targeting antibodies. The firm also carries out preclinical development, including work on programs, to evaluate drug behavior and readiness before entering human studies. In addition, It conducts clinical development services by sponsoring and managing trials for its pipeline, assessing safety, tolerability, pharmacokinetics, and pharmacodynamics.

Industry: Biological Products, (No Diagnostic Substances)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support